| Barre Gardens Nursing And Rehab Llc | |
| 378 Prospect Street, Barre, Vermont 05641 | |
| (802) 476-4166 | |
| Name | Barre Gardens Nursing And Rehab Llc |
|---|---|
| Location | 378 Prospect Street, Barre, Vermont |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 96 |
| Occupancy Rate | 83.65% |
| Medicare ID (CCN) | 475037 |
| Legal Business Name | Barre Gardens Nursing And Rehab Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1831180116 |
| Organization Name | BARRE GARDENS NURSING AND REHAB LLC |
| Address | 378 Prospect Street, Barre, VT 05641 |
| Phone Number | 802-476-4166 |
News Archive
Researchers may have come one step closer toward understanding how the immune system contributes to severe COVID-19.
Patients with acne and rosacea are often confused about selecting appropriate skin care products, cosmeceuticals and cosmetics to add into their daily routine. While they want to continue to see results with the treatment regimen from their dermatologist, they also want to be comfortable using products that address other skin issues, such as wrinkles or that protect their skin, such as sunscreens.
CytoDyn, Inc. has begun full humanization of Cytolin®, the Company's unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.
Researchers have provided new insight into the cellular processes behind the 'shock and kill' approach to curing HIV, which they say challenges the effectiveness of the treatment.
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Researchers may have come one step closer toward understanding how the immune system contributes to severe COVID-19.
Patients with acne and rosacea are often confused about selecting appropriate skin care products, cosmeceuticals and cosmetics to add into their daily routine. While they want to continue to see results with the treatment regimen from their dermatologist, they also want to be comfortable using products that address other skin issues, such as wrinkles or that protect their skin, such as sunscreens.
CytoDyn, Inc. has begun full humanization of Cytolin®, the Company's unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.
Researchers have provided new insight into the cellular processes behind the 'shock and kill' approach to curing HIV, which they say challenges the effectiveness of the treatment.
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $8294 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 16.49 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 10.93 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 63.37 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 4.95 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 4.41 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 21.43 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.04 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 92.86 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 12.64 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 90.84 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.3 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 29.15 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 16.38 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.5 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 88.3 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 84.02 | 82.93 |
News Archive
Researchers may have come one step closer toward understanding how the immune system contributes to severe COVID-19.
Patients with acne and rosacea are often confused about selecting appropriate skin care products, cosmeceuticals and cosmetics to add into their daily routine. While they want to continue to see results with the treatment regimen from their dermatologist, they also want to be comfortable using products that address other skin issues, such as wrinkles or that protect their skin, such as sunscreens.
CytoDyn, Inc. has begun full humanization of Cytolin®, the Company's unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.
Researchers have provided new insight into the cellular processes behind the 'shock and kill' approach to curing HIV, which they say challenges the effectiveness of the treatment.
› Verified 9 days ago
Barre Gardens Nursing And Rehab Llc Location: 378 Prospect Street, Barre, Vermont 05641 Phone: (802) 476-4166 | |